609 related articles for article (PubMed ID: 27291669)
1. Extracellular Volume Detects Amyloidotic Cardiomyopathy and Correlates With Neurological Impairment in Transthyretin-familial Amyloidosis.
Gallego-Delgado M; González-López E; Muñoz-Beamud F; Buades J; Galán L; Muñoz-Blanco JL; Sánchez-González J; Ibáñez B; Mirelis JG; García-Pavía P
Rev Esp Cardiol (Engl Ed); 2016 Oct; 69(10):923-930. PubMed ID: 27291669
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
3. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
[TBL] [Abstract][Full Text] [Related]
5. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
[TBL] [Abstract][Full Text] [Related]
6. Cardiac amyloidosis: updates in diagnosis and management.
Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy.
Sha Q; Zhang Y; Wang M; Sun J; Zhang Y; Zhang X; Wang N; Liu Y; Liu Y
ESC Heart Fail; 2024 Feb; 11(1):112-125. PubMed ID: 37827496
[TBL] [Abstract][Full Text] [Related]
8. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
9. Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging.
Barison A; Aquaro GD; Pugliese NR; Cappelli F; Chiappino S; Vergaro G; Mirizzi G; Todiere G; Passino C; Masci PG; Perfetto F; Emdin M
J Intern Med; 2015 May; 277(5):605-14. PubMed ID: 25346163
[TBL] [Abstract][Full Text] [Related]
10. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope.
González-López E; López-Sainz Á; Garcia-Pavia P
Rev Esp Cardiol (Engl Ed); 2017 Nov; 70(11):991-1004. PubMed ID: 28870641
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart failure.
Gagliardi C; Perfetto F; Lorenzini M; Ferlini A; Salvi F; Milandri A; Quarta CC; Taborchi G; Bartolini S; Frusconi S; Martone R; Cinelli MM; Foffi S; Reggiani MLB; Fabbri G; Cataldo P; Cappelli F; Rapezzi C
Eur J Heart Fail; 2018 Oct; 20(10):1417-1425. PubMed ID: 30070416
[TBL] [Abstract][Full Text] [Related]
13. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
14. Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy.
Minutoli F; Di Bella G; Mazzeo A; Donato R; Russo M; Scribano E; Baldari S
AJR Am J Roentgenol; 2013 Mar; 200(3):W256-65. PubMed ID: 23436870
[TBL] [Abstract][Full Text] [Related]
15. Speckle Tracking and Transthyretin Amyloid Cardiomyopathy.
Rocha AM; Ferreira SG; Nacif MS; Ribeiro ML; Freitas MR; Mesquita CT
Arq Bras Cardiol; 2017 Jan; 108(1):21-30. PubMed ID: 27992035
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild-Type Transthyretin Amyloid Cardiomyopathy.
Morioka M; Takashio S; Nakashima N; Nishi M; Fujiyama A; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Kidoh M; Oda S; Matsushita K; Ueda M; Tsujita K
J Am Heart Assoc; 2022 Jun; 11(12):e024717. PubMed ID: 35699194
[TBL] [Abstract][Full Text] [Related]
17. Early Detection of Cardiac Amyloidosis in Transthyretin Mutation Carriers.
Nagano N; Muranaka A; Nishikawa R; Ohwada W; Kouzu H; Kamiyama N; Fujito T; Mochizuki A; Nagahara D; Nakanishi M; Ohkubo Y; Hisahara S; Nakao S; Katoh N; Ishikawa A; Sakurai A; Yano T
Int Heart J; 2022; 63(1):168-175. PubMed ID: 35095067
[TBL] [Abstract][Full Text] [Related]
18. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
[TBL] [Abstract][Full Text] [Related]
19. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
20. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.
Damy T; Judge DP; Kristen AV; Berthet K; Li H; Aarts J
J Cardiovasc Transl Res; 2015 Mar; 8(2):117-27. PubMed ID: 25743445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
